NCT07226843

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 360 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

Conditions

• Lymphoma, Non-Hodgkin's
• Lymphoma, Diffuse Large B-Cell
• Follicular Lymphoma

Interventions

Type	Name	Description
DRUG	LY4584180	administered orally
DRUG	Rituximab	administered through IV infusion

Timeline

• Start date: 2026-04-01
• Primary completion: 2027-02-01
• Completion: 2029-12-01
• First posted: 2025-11-12
• Last updated: 2026-04-17

Locations

45 sites across 8 countries: United States, France, Germany, Italy, Japan, Poland, Spain, United Kingdom

Regulatory

• FDA-regulated drug study